DETECTION OF MULTI-DRUG RESISTANCY IN MALIGNANT BONE AND SOFT TISSUE TUMORS BY ADRIAMYCIN BINDING ASSAY

阿霉素结合试验检测恶性骨和软组织肿瘤的多药耐药性

基本信息

批准号：
05671224
负责人：
KUSUZAKI Katsuyuki
金额：
$ 1.02万
依托单位：
KYOTO PREFECTURAL UNIVERSITY OF MEDICINE
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1993
资助国家：
日本
起止时间：
1993 至 1994
项目状态：
已结题

项目摘要

In this study, the author first, developed in vivo method of adriamycine Binding Assay (ABA) which has been proved to be able to quickly detect sensitivity not only to adriamycine (ADR) also to multi-anticancer drugs in cultured cell lines and secondly, investigated relationship between adriamycin binding ratio and clinical or histological effect of chemotherapy in human bone nad soft tissue tumors. Living tumor cells were isolated from fresh biopsied materials with collagenase and incubated with 10ug/ml ADR for 30 min. Only living cells were then stained with fluorescein diacetate (FDA). Under observation with fluorescence microscope, the living cells with ADR fluorescence in nucleus were evaluated to be sensitive to ADR,but ones without ADR were resistant. %AB showed frequency of sensitive cells in all of the living cells measured. Fourty-four patients were analyzed. In most of the patients with recurrence or metastasis after chemotherapy to primary tumor, or with metastatic disease at diagnosis of primary tumor, %AB was less than 80%. This strongly suggests that tumors with low %AB are multi-drug resistant. Of 11 patients with primary tumor lesion without metastasis and any kind of previous chemotherapy, 4 with %AB more than 80% were histologically sensitive to chemotherapy after preoperative chemotherapy, whereas remaining 7 with %AB less than 80% except one were resistant. It also shows that %AB is correlated with chemotherapy effect well. The author, therefore concluded that ABA is one of the excellent chemosensitivity tests and avalable to clinical usage, because it is able to predict sensitivity to chemotherapy more quickly and accurately than other chemosensitivity tests previously reported.

In this study, the author first, developed in vivo method of adriamycine Binding Assay (ABA) which has been proved to be able to quickly detect sensitivity not only to adriamycine (ADR) also to multi-anticancer drugs in cultured cell lines and secondly, investigated relationship between adriamycin binding ratio and clinical or histological effect of chemotherapy in human bone nad soft tissue tumors.将活肿瘤细胞从新鲜的活检材料与胶原酶分离出来，并与10ug/ml ADR孵育30分钟。然后，仅将活细胞用荧光素二乙酸酯（FDA）染色。在使用荧光显微镜观察的情况下，评估了核中ADR荧光的活细胞对ADR敏感，但没有ADR的活细胞具有抗性。％AB在所有测量的活细胞中显示敏感细胞的频率。分析了四十四名患者。在化学疗法对原发性肿瘤化疗后复发或转移的大多数患者中，或诊断为原发性肿瘤时的转移性疾病，％AB的患者小于80％。这强烈表明，低％AB的肿瘤具有多药耐药性。在11例没有转移的原发性肿瘤病变和任何类型的化学疗法的患者中，4％以上的AB患者在术前化学疗法后对化学疗法的组织学敏感，而剩余7％的AB小于80％，除了抗性。它还表明％AB与化学疗法效应良好相关。因此，作者得出的结论是，ABA是出色的化学敏度测试之一，可用于临床使用，因为它能够比以前报道的其他化学效率测试更快，准确地预测对化学疗法的敏感性。